CSF sulfatide is decreased in individuals with incipient dementia Xianlin Han, PhD, Anne M. Fagan, PhD, Hua Cheng, MS, John C. Morris, MD, Chengjie Xiong,

Slides:

Advertisements

Similar presentations

ERP Characteristics of Early AD

Advertisements

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.

Speed of processing, the missing measure in early detection of MCI? Ruth O’Hara March 13 th 2001 Yogesh Shah.

Department of Neurology, Mayo Clinic Arizona

Supported by grants from: National Human Genome Research Institute (ELSI) HG/AG (The REVEAL Study); National Institute on Aging AG (The MIRAGE.

PRACTICE PARAMETER: RISK OF DRIVING AND ALZHEIMER ’ S DISEASE (AN EVIDENCE-BASED REVIEW) Richard M. Dubinsky, MD; Anthony C. Stein, PhD; and Kelly Lyons,

Frontotemporal Dementia

Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Householder, MS.

Presymptomatic HD Disease onset currently defined by clinical detection of motor abnormalities Questions: 1) Are more subtle but clinically important signs.

Population-based Neuropathology: classification of disease biomarker discovery tool Thomas J. Montine, MD, PhD Alvord Professor and Chair Department of.

CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.

Mary Ganguli’s Slides March 13 th Meeting. Mild Cognitive Impairment A View from the Trenches.

Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.

Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.

Dementia with Lewy Bodies

Mild Cognitive Impairment

Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI.

Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Franklin, MS Presented by: Beau Ances,

Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.

Risk of Developing Alzheimer’s Disease in Persons with MCI

Body Mass Index Changes in Prodromal Huntington Disease Nancy R. Downing, PhD, RN CANS September 13, 2012.

Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.

A New Method for Mapping the Linkage between Abnormal Gray Matter Loss and the Clinical and Cognitive Deficits in Childhood-Onset Schizophrenia 1 Christine.

Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.

Are spatial tasks useful for the early diagnosis of Alzheimer’s disease.

MCI Conversion to Dementia: Clinic and Community-Based Studies

CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.

Oregon Health & Science University and Northwest PADRECC

Dennis Bourdette, MD VA MS Center of Excellence-West and

Clinical, cognitive and genetic predictors of conversion from amnestic mild cognitive impairment to Alzheimer’s disease in Chinese older adults (Chu LW,

Recent advances in Trace Element Research in Health and Disease Dubrovnik, Oct 2015 Mirjana Babić Leko, mag.biol.mol Department of Neuroscience Croatian.

White Matter Structural Integrity in Healthy Aging Adults and Patients With Alzheimer Disease: A Magnetic Resonance Imaging Study Bartzokis, et al. UCLA.

Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Methods, Results and Limitations of Studies of Brain Iron in RLS in the Living Christopher J Earley MB, BCh, PhD, FRCP(I) Professor Department of Neurology.

The role of Nutrition in Geriatric Mental Health Chih-Chiang Chiu, M.D., Ph.D. Department of Psychiatry, Taipei City Psychiatric Center.

STUDY ON THE LEVELS OF TAU AND β-AMYLOID IN CSF OF PATIENTS WITH MULTIPLE SCLEROSIS Levente Szalárdy MD Department of Neurology University of Szeged Hungary.

INFLUENCE OF FRACTIONAL ANISOTROPY THRESHOLD FOR TRACT BASED DIFFUSION TENSOR ANALYSIS OF UNCINATE FASCICLES IN ALZHEIMER DISEASE Toshiaki Taoka, Toshiaki.

Aka STEEL VALLEY SENIORS SURVEY (SVSS)

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease Mirjana Babić.

Volume 3, Issue 4, Pages (November 2017)

Metabolic Syndrome and Progression of Mild Cognitive Impairment

Table 1. Summary of Study Measures

Brief Computerized Measures of Information Processing Speed are Sensitive to Multiple Sclerosis across the Lifespan M. Shaw1, C. Schwarz1, L.B. Krupp1,

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

CRAHW Centre for Research on Ageing, Health & Wellbeing

BACKGROUND RESULTS OBJECTIVES METHODS CONCLUSIONS REFERENCES

Volume 2, Issue 1, Pages (January 2016)

Imaging AD Progression Amyloid Imaging Agents.

PPMI in the Medical Literature

Figure 2 Overview of risk factors for Parkinson disease dementia

Early Cognitive Decline and the Aging Brain - Overview

Early Dementia Distinguishing AD From MCI

Reisa Sperling, Elizabeth Mormino, Keith Johnson Neuron

Blood-Based Biomarkers in the QC Program?

Adam P. Spira, Ph.D. Associate Professor, Department of Mental Health

Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W

Biomarker Modeling of Alzheimer’s Disease

Cognitive Reserve Concepts

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.

Rubin Becker MD FRCP© Associate Professor McGill University Medical Consultant Manulife and OptimumRe.

Elucidating the Role of TREM2 in Alzheimer’s Disease

Baseline Characteristics of the Subjects

Massimo S. Fiandaca, Mark E. Mapstone, Amrita K. Cheema, Howard J

in Younger and Older African Americans and Whites

Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI

Presentation transcript:

CSF sulfatide is decreased in individuals with incipient dementia Xianlin Han, PhD, Anne M. Fagan, PhD, Hua Cheng, MS, John C. Morris, MD, Chengjie Xiong, PhD, David M. Holtzman, MD Washington University School of Medicine Department of Medicine and Neurology

Progression Time Cognitive Function Pre-clinical Very Mild CDR 0.5 MCI Clinical detection threshold Mild CDR1 Stage of dementia Moderate Severe AD pathological burden Onset of AD pathology

An unbiased screen of normal and AD brain tissue using ESI- mass spectrometry led to identification of marked decline in sulfatide in both gray and white matter at CDR 0.5 level of dementia due to AD. *Most other lipids were unchanged. Han et al. J. Neurochem. 2002

Sulfatide: a sulfated galactocerebroside * synthesized by oligodendrocytes * buildup due to sulfatidase deficiency causes metachromatic leukodystrophy * present in lipoprotein particles along with apoE in the CNS

Electrospray ionization mass spectrometry: Decrease in sulfatides in very mild AD frontal grey matter vs. control

Characteristics of initial group in CSF study All CSF and plasma was collected fasting at 8AM Samples were stored at –70 o C till analyzed

CSF sulfatide (ST) is markedly and significantly lower in CDR 0.5 vs. CDR 0 subjects

Sensitivity and specificity of CSF sulfatide/PI ratio in differentiating CDR 0 from CDR 0.5 subjects is better in this sample than several other established AD biomarkers Sens=90% Spec=100%

Future Questions to be addressed 1.Does sulfatide or the ST/PI ratio differentiate subjects who have a CDR score of 0 from a score of 0.5 and greater in other samples? 2.Are there storage or collection issues that are critical in assessment of this CSF biomarker? 3. Does a low ST/PI ratio increase risk of converting from CDR 0 to CDR 0.5 or from CDR 0.5 to 1? 4. Is a decrease in ST/PI ratio specific for AD vs. other neuro-degenerative diseases (e.g. Parkinson’s, frontotemporal dementia, etc.).

CSF sulfatide is decreased in a large sample of AD vs. controls subjects (samples from Joseph Quinn, MD, PhD, Oregon Health Sciences)